CurrentBlue Cross Blue Shield - TennesseePolicy N/A
Pancreatic Enzyme Testing for Acute Pancreatitis
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
Describes coverage criteria for measurement of pancreatic enzyme biomarkers (serum lipase, serum amylase, urinary amylase, trypsin/trypsinogen/TAP, and inflammatory biomarkers) for diagnosis, prognosis, severity assessment, and monitoring of acute and chronic pancreatitis for Blue Cross Blue Shield - Tennessee members.
Policy Summary
PayerBlue Cross Blue Shield - Tennessee
PolicyPancreatic Enzyme Testing for Acute Pancreatitis
Policy CodePolicy N/A
Change TypeN/A
Effective DateJul 1, 2023
Next Review DateN/A
Key ActionOrder serum lipase (preferred) OR amylase for initial diagnosis of acute pancreatitis; avoid ordering both tests together.
SourceLink
POLICY UPDATE CHANGES
No material clinical or coverage changes in this revision.
Coveredcoverage position for initial diagnosis
Not covereddouble-testing rule
Not coveredurinary amylase stance
2023-07-01effective date
7CPT/HCPCS listed
Coverage Criteria for Pancreatic Enzyme and Biomarker Testing
Coverage Criteria for Pancreatic Enzyme and Biomarker Testing
Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in Section VII of this policy document.
ALL of the following
- Measurement of either serum lipase (preferred) OR amylase concentration for the initial diagnosis of acute pancreatitis meets coverage criteria in all patients presenting with signs and symptoms of acute pancreatitis (see Note 1).
Not covered situations
- Measurement of either serum lipase (preferred) OR amylase concentration as part of an ongoing assessment of therapy for acute pancreatitis.
- Measurement for determining the prognosis of pancreatitis.
- Measurement for determining the severity or progression of pancreatitis.
- Measurement performed more than once per visit.
- Measurement for the diagnosis, prognosis, or severity of chronic pancreatitis.
- Measurement as part of ongoing assessment or therapy of chronic pancreatitis.
- Measurement in asymptomatic nonpregnant individuals during general exam without abnormal findings.
- Measurement of both amylase AND serum lipase for diagnosis or assessment of acute pancreatitis does not meet coverage criteria.
- Measurement of serum or urine trypsin/trypsinogen/TAP (trypsinogen activation peptide) for diagnosis or assessment of acute pancreatitis does not meet coverage criteria.
Biomarkers considered not meeting coverage criteria due to insufficient evidence
- C-reactive protein (CRP) for diagnosis or determination of severity of acute pancreatitis does not meet coverage criteria.
- Interleukin-6 (IL-6) for diagnosis or determination of severity of acute pancreatitis does not meet coverage criteria.
- Interleukin-8 (IL-8) for diagnosis or determination of severity of acute pancreatitis does not meet coverage criteria.
- Procalcitonin for diagnosis or determination of severity of acute pancreatitis does not meet coverage criteria.
- Measurement of urinary amylase concentration for the initial diagnosis of acute pancreatitis does not meet coverage criteria in all patients presenting with signs and symptoms of acute pancreatitis (see Note 1).
COVERAGE CRITERIA — stance on biochemical tests for diagnosis and monitoring of acute pancreatitis with supporting evidence/guidelines
Current guideline and evidence-based stance on biochemical tests for diagnosis and monitoring of acute pancreatitis:
ALL of the following
- Major society guidelines endorse using the revised Atlanta classification: diagnosis requires ≥2 of the following — characteristic abdominal pain, serum amylase or lipase >3× upper limit of normal, or imaging consistent with pancreatitis.
- Serum lipase is preferred over amylase due to higher sensitivity and a longer diagnostic window; lipase levels remain elevated longer, improving detection when presentation or testing is delayed.
- Either serum amylase or serum lipase should be tested within 48 hours of admission; lipase is preferred when available.
- Routine or serial daily measurement of amylase or lipase after diagnosis has limited value for assessing clinical progress and is not recommended for monitoring prognosis or severity in the absence of new/worsening symptoms.
- Testing both amylase and lipase simultaneously is discouraged: it increases cost with only marginal diagnostic benefit over lipase alone.
- Some biomarkers (CRP, IL-6, IL-8, procalcitonin, trypsinogen/TAP) have been evaluated for prognosis/severity assessment, but available evidence does not support their routine use for diagnosis or standard assessment of severity; recommendations vary and many remain not routinely endorsed for initial diagnosis.
See professional society guidance summaries (IAP/APA, AGA, ACG, ABIM/ASCP/Choosing Wisely) for specifics on thresholds (commonly ≥3× ULN) and context for use of CRP for severity assessment (eg, CRP >150 mg/L at 48 hours may be used as an adjunct).
coverage criteria and guidance — summarized guidance from professional societies and reimbursement policy statements
Summarized guidance from professional societies and reimbursement policy statements relevant to ordering and reimbursement:
ALL of the following
- Do not order amylase if serum lipase testing is available for diagnosis and management of acute pancreatitis; amylase may be considered only when lipase is unavailable as a stat test and clinical presentation warrants urgent testing.
- Amylase is nonspecific and can be elevated in many non-pancreatic conditions; avoid routine amylase testing for pancreatitis when lipase is available.
- Discourage co-ordering of amylase and lipase as a default order set; removing amylase from common order sets reduces unnecessary testing and costs.
- Repeat pancreatic enzyme testing should be limited to situations with new or persisting signs of pancreatic or peripancreatic inflammation, suspected ductal obstruction, or development of complications such as pseudocyst.
- Some society positions note threshold values (commonly ≥3× upper limit of normal) for diagnostic consideration; however, some groups advise against rigid reliance on arbitrary multiples (eg, UK Working Party commentary).
Regulatory, test classification, and coding notes — FDA/LDT/classification and coverage-related statements
Regulatory status, test classification, and coding notes relevant to coverage and billing:
ALL of the following
- FDA has approved multiple serum assays for total and pancreatic amylase and for serum lipase; these are cleared in vitro diagnostics when marketed as such.
- Trypsin immunostaining, trypsinogen-2 dipstick, and TAP assays are typically laboratory-developed tests (LDTs) and are regulated under CLIA as high-complexity tests; they have not received FDA clearance/approval for these specific LDT implementations.
- IL-6 and IL-8 assays are commonly ELISA-based and are often offered as LDTs or as part of cytokine panels; availability and validation vary by laboratory.
- CRP and procalcitonin assays: multiple FDA-cleared assays exist for CRP and for procalcitonin (eg, Diazyme PCT assay, Atellica IM BRAHMS PCT device), reflecting cleared options for these biomarkers when clinically indicated.
- Applicable CPT codes include: 82150 (amylase), 83690 (lipase), 84145 (procalcitonin), 86140 (C-reactive protein), 83529 (interleukin-6), and immunoassay codes 83519/83520 for quantitative immunoassays; laboratories should bill using the appropriate CPT that reflects the specific assay performed and its regulatory status.
Applicable Codes, Coding Notes, and Thresholds
applicable CPT/HCPCSmixed
| No codes listed |
coding notesmixed
| No explicit CPT/HCPCS/ICD codes present in this excerpt |
FDA-cleared assaysmixed
| FDA has approved multiple tests for serum total and pancreatic amylase | |
| FDA has approved multiple tests for serum lipase |
Applicable procedure codesCPT
| 82150 | Amylase |
| 83519 | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA) |
| 83520 | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified |
| 83529 | Interleukin-6 (IL-6) |
| 83690 | Lipase |
| 84145 | Procalcitonin (PCT) |
| 86140 | C-reactive protein |
inv-09: diagnostic threshold (general guideline)
Diagnostic threshold (general guideline)Serum lipase or amylase ≥ 3× upper limit of normal (URL) is diagnostic when combined with clinical criteria (pain or imaging)
Clinical requirementDiagnosis requires at least 2 of 3 Atlanta criteria: characteristic abdominal pain, enzyme elevation ≥3× URL, or characteristic imaging findings
Source guideline referenceAtlanta classification (revised 2012) commonly used by major societies
inv-10: diagnostic enzyme threshold — >3× upper limit of normal (Atlanta classification)
Atlanta classification threshold>3× upper limit of normal (URL) for serum amylase or lipase per Atlanta criteria
Society endorsementIAP/APA and AGA/ACG cite >3× URL as diagnostic cut-off in guideline statements
ApplicationUsed as one of two required findings (with pain or imaging) to establish diagnosis
inv-11: diagnostic threshold — commonly ≥3× URL; some societies vary (2–4×) or use time-based interpretation
Common practiceMost professional groups commonly use a ≥3× URL threshold for serum pancreatic enzymes
VariabilitySome societies or working groups interpret thresholds relative to time since pain onset or allow ranges of ~2–4× URL rather than strict cut-offs
Time-based considerationUK Working Party and other guidelines caution against reliance on arbitrary fixed multiples and recommend interpreting enzyme values in clinical context and timing
Provider Actions, Ordering and Billing Guidance
Note
Use of inflammatory markers for severity assessment
Use inflammatory markers (for example, CRP, procalcitonin, IL-6, LDH, serum cholinesterase) only when needed for prognostic assessment or as adjuncts to clinical and imaging evaluation. These markers have shown prognostic value for severity and mortality in acute pancreatitis but are not routinely covered for ongoing monitoring or as standalone diagnostic tests. Prefer imaging (CT) and validated clinical severity scores (e.g., APACHE-II) over routine serial inflammatory-marker measurement for severity assessment. If inflammatory markers are used, document the specific clinical question (prognosis, suspected necrosis, or organ failure) and how the result will change management to support medical necessity.
- CRP: may help detect pancreatic necrosis (maximal at 48–72 hours) but sensitivity/specificity limitations — not for routine serial monitoring.
- Procalcitonin, IL-6, IL-8, LDH: have prognostic value in studies but limited routine coverage; consider when results will impact escalation of care.
- Serum cholinesterase: associated with severity/mortality in cohort studies but not a routine covered test for monitoring.
- Document clinical indication (e.g., suspected infected necrosis, unexplained deterioration, organ failure) to justify testing.
Definitions, Test Characteristics, and Background
inv-19: Acute pancreatitis (AP) definition and diagnostic criteria overview
Definition of APAcute pancreatitis is inflammation of the pancreatic tissue; diagnosis requires at least 2 of 3 features: characteristic abdominal pain, serum lipase or amylase ≥3× URL, or characteristic imaging findings (CECT/MRI/ultrasound)
Temporal phasesAP may be characterized by early or late phases with varied severity
Consensus originDiagnostic criteria derive from the Atlanta classification (1992, revised 2012)
inv-20: Amylase / Lipase — timing, elevation duration, and preference for lipase
Timing of riseLipase and amylase increase within ~3–6 hours after pancreatic injury
Duration of elevationSerum lipase remains elevated ~1–2 weeks (commonly 8–14 days); amylase returns to normal much sooner (half-life ~12 hours)
Test preferenceLipase is preferred due to greater sensitivity, specificity, and longer diagnostic window
inv-21: Diagnosis of acute pancreatitis — Atlanta/major society criteria summary
Atlanta/major society criteriaDiagnosis requires ≥2 of: characteristic abdominal pain; biochemical evidence (amylase or lipase >3× URL); or radiographic evidence of pancreatitis
Society consensusIAP/APA, AGA, ACG and others endorse the two-of-three diagnostic framework
Practical noteEnzyme testing should be interpreted alongside timing of symptom onset and imaging; do not rely solely on serial enzyme measurements for prognosis
inv-22: Urine trypsinogen-2 dipstick (UTDT) — point-of-care urine test characteristics and regulatory status
Test descriptionUrine trypsinogen-2 dipstick is a point-of-care urine test detecting urinary trypsinogen-2 (eg, Actim Pancreatitis test strip)
Performance characteristicsReported sensitivity/specificity vary by study (examples: specificity 85% for severe AP; sensitivity reported 67–94% across studies)
Regulatory statusAs of 2020 the FDA has not approved the trypsinogen-2 dipstick for detection/diagnosis of AP in the U.S.; clinical trials ongoing
inv-23: serum lipase — preferred test
Preferred analyteSerum lipase is the preferred test for initial diagnosis of acute pancreatitis
Diagnostic advantageLipase has higher sensitivity and specificity than amylase and a wider diagnostic window, making it more useful when presentation is delayed
Clinical guidanceDo not order amylase if lipase is available; consider amylase only if lipase is not available as a stat test
inv-24: serum amylase — less specific; consider when lipase not available
Specificity limitationsAmylase is less specific than lipase and can be elevated from nonpancreatic causes (eg, salivary disease, intestinal pathology, macroamylasemia)
Timing constraintAmylase rises early but has a short half-life (~12 hours) and often normalizes quickly, reducing diagnostic value if testing is delayed
Use caseConsider measuring amylase only when serum lipase is not available as a stat test; routine dual-ordering with lipase is discouraged
inv-25: Laboratory developed test (LDT) — definition and regulatory note
DefinitionLaboratory-developed tests (LDTs) are assays developed, validated and performed by individual laboratories
Regulatory noteLDTs are regulated by CMS as high-complexity tests under CLIA '88; FDA approval/clearance is not required for LDT clinical use
Examples in policyTrypsin immunostaining, trypsinogen-2 dipstick, and TAP serum tests are characterized as LDTs in this policy
inv-26: C-reactive protein (CRP) assays — FDA approvals and assay types
Regulatory approvalsFDA has approved multiple assays for conventional CRP, high-sensitivity CRP (hsCRP), and cardiac CRP (cCRP); FDA issued assessment guidance for CRP in 2005
Clinical timingCRP peaks 48–72 hours after symptom onset and is used for severity/necrosis assessment rather than initial diagnosis
Role in APCRP is widely studied for prognostication but is not practical for early diagnosis due to delayed accuracy
inv-27: Procalcitonin (PCT) assay — device approvals and notes
Device approvalsSpecific procalcitonin assays/devices have received FDA clearance/approval (eg, Diazyme PCT assay in 2017; Atellica IM BRAHMS PCT device in 2018)
Prognostic useProcalcitonin has been studied for early assessment of pancreatic infection and prognosis in severe AP but is not recommended as a sole triage marker
Evidence sourcesProspective and multicenter studies cited for PCT utility in assessing infection and prognosis
inv-28: References / Guidelines — bibliographic references and guideline sources
Guideline and literature sourcesKey references include Atlanta classification papers, ACG 2013 guideline, AGA 2018 guideline, Cochrane review (Rompianesi et al. 2017), and multiple primary studies and reviews
Systematic reviewsCochrane review on serum amylase/lipase and urinary trypsinogen/amylase for AP diagnosis is cited
Additional studiesSelected studies on urinary trypsinogen/TAP, CRP, procalcitonin, and enzyme behavior are listed (eg, Neoptolemos 2000; Yasuda 2019; Tenner et al. 2013)
Policy Summary
PayerBlue Cross Blue Shield - Tennessee
PolicyPancreatic Enzyme Testing for Acute Pancreatitis
Policy CodePolicy N/A
Change TypeN/A
Effective DateJul 1, 2023
Next Review DateN/A
Key ActionOrder serum lipase (preferred) OR amylase for initial diagnosis of acute pancreatitis; avoid ordering both tests together.
SourceLink
On This Page
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.